Drug & intervention
Lantus
RxCUI 261551
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Lantus
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
9 shownA Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 DiabetesNCT02514850 · 2015-07-01
COMPLETEDComparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different RegimensNCT02587741 · 2015-07-01
UNKNOWNA Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes MellitusNCT01600950 · 2012-05-01
COMPLETEDA Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy ParticipantsNCT01476345 · 2011-11-01
COMPLETEDA Study in Adults With Type 2 DiabetesNCT01421459 · 2011-09-01
COMPLETEDA Study in Adults With Type 1 DiabetesNCT01421147 · 2011-08-01
COMPLETEDA Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy SubjectsNCT01374178 · 2011-06-01
COMPLETEDPerioperative Insulin Glargine Dosing StudyNCT00309465 · 2005-10-01
COMPLETEDLANN-study: Lantus, Amaryl, Novorapid, Novomix StudyNCT00151697 · 2005-05-01
COMPLETEDConditions being studied
Research locations
AshevilleNorth Carolina, United States2AtlantaGeorgia, United States2BudapestHungary2DallasTexas, United States2Des MoinesIowa, United States2HamburgGermany2HeidelbergGermany2MonterreyMexico2New Hyde ParkNew York, United States2OmahaNebraska, United States2San AntonioTexas, United States2SyracuseNew York, United States2
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.